A Randomized Controlled Postoperative Adjuvant Chemotherapy Trial of MMC+Tegafur and MMC+UFT for Adenocarcinoma of the Lung-First Study (Second Report) :

1 Citations

Bibliographic Information

Other Title
  • 肺腺癌に対する術後補助化学療法の検討.-第1次研究 : MMC+Tegafur とMMC+UFTの比較試験-(第2報)

Search this article

Abstract

The usefulness of adjuvant chemotherapy in patients with pulmonary carcinoma undergoing curative resection was jointly studied by 30.institutions in Western Japan. The results of this trial after a 5-year follow-up are reported here. The subjects were patients with pulmonary adenocarcinoma who underwent absolutely or relatively curative resection. They were treated with 20+10mg MMC, plus 600mg tegafur orally for one year(Group A) or with 20+10mg MMC, plus 400-600mg UFT orally for one year (Group B). Between November 1982 and November 1985, 224 patients received this therapy (113 in Group A, and 111 in group B). Excluding 43 cases which were judged inappropriate for evaluation, 88 patients in Group A and 93 in Group B were evaluated. There was no significant difference in any background variable between the two groups. The overall 5-year survival rate did not significantly differ between Group A (64.3%) and Group B (55.6%). The overall 5 year disease-free rate also did not significantly differ between the two groups. In stratified analysis, N2 cases in group B had higher 5-year survival and recurrence-free rates than those in Group A (p=0.029 and 0.048, respectively).

Journal

Citations (1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top